Castle Biosciences (CSTL) vs Fulgent Genetics (FLGT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Castle Biosciences (CSTL) has outperformed Fulgent Genetics (FLGT) over the past year, gaining 44.0% versus a loss of 8.8%. Over five years, CSTL leads with a -48.1% price change compared with -73.3% for FLGT. Castle Biosciences is the larger company by market cap ($1.03 billion vs $572.9 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSTL | FLGT |
|---|---|---|
| Share price | $33.71 | $20.82 |
| Market cap | $1.03B | $572.87M |
| 1-day change | +2.15% | +1.22% |
| YTD return | -15.17% | -20.75% |
| 1-year return | +43.98% | -8.80% |
| 5-year return | -48.10% | -73.31% |
| EPS (TTM) | $-0.64 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.28 | $31.04 |
| 52-week low | $17.72 | $13.46 |
| Distance from 52-week high | -23.87% | -32.93% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +33.82% | -8.74% |
| Average volume | 401.17K | 298.26K |
| Shares outstanding | 30.55M | 27.52M |
| Employees | 1,002 | 1,315 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSTL has outperformed FLGT by 52.8 percentage points over the past year.
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Health Care · Medical Specialities · 1,002 employees
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Health Care · Medical Specialities · 1,315 employees
CSTL vs FLGT FAQ
Which is bigger, Castle Biosciences or Fulgent Genetics?
Castle Biosciences (CSTL) is larger, with a market capitalization of $1.03B compared with $572.87M for Fulgent Genetics (FLGT).
Which stock has performed better over the past year, CSTL or FLGT?
CSTL returned +43.98% over the past 12 months, compared with -8.80% for FLGT (price return, excluding dividends). Past performance does not predict future results.
Are Castle Biosciences and Fulgent Genetics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.